Thanks

That's great for Zenith shareholders and for Zenith. The fact that RVX is not a one trick pony, as you said, is a total game changer. The most recent Zach's analysis gave a target of $3. We now have two reasons to adjust that price. The start of BetonMace will increase the probablity of RVX success which lowers the discount rate on future revenues increasing the valuation. Multiple indications and trials will multiply the value. I would expect a formidable increase in the target price soon. Today's release and upcoming news should lead to more coverage.

Chicagoest